Biogen Inc. (NASDAQ:BIIB), a leading biopharmaceutical company specializing in neurology and rare diseases, finds itself at a critical juncture as it navigates a complex landscape of opportunities and ...

The global neuromuscular disease therapeutics market is projected to grow by $13.73 billion between 2025 and 2029, according ...

Securities adjusted its outlook on Sage Therapeutics (NASDAQ:SAGE) shares, with analyst Vamil Divan increasing the price target to $9.00 from the previous $6.00, while maintaining a Neutral rating on ...

Truist has initiated coverage of Larimar (LRMR) with a buy rating, citing an "asymmetric" risk/reward ahead of regulatory ...

In a report released today, David Amsellem from Piper Sandler maintained a Hold rating on Biogen (BIIB – Research Report), with a price target ...

US stocks closed in the red on Wednesday after the Federal Reserve said it would bide its time before making any further ...

Boston Properties (NYSE:BXP) reported its fourth-quarter 2024 earnings, revealing a significant miss on earnings per share ...

U.S. Bancorp Dep. Pfd. (Rep. 1/1000th Non-Cum. Perp. Pfd. Series K)-0.83% U.S. Bancorp Dep. Pfd. (Rep. 1/1000th Perp. 3.75% Pfd. Series L)-0.72% U.S. Bancorp Dep. Pfd ...

On to its next chapter. Our research team assigns Bronze ratings to strategies they’re confident will outperform a relevant index, or most peers, over a market cycle on a risk-adjusted basis ...

It was a busy week for the biotech sector, with regulatory and pipeline updates. Sage Therapeutics SAGE was in focus after it ...

Trade Desk Inc. Cl A $122.59 2.03 1.68% ...

Dell Technologies Inc. Cl C 1.79% $71.07B ...